The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001364369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/10/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Agreement between a robotic ultrasound system (VxWave) and a standard handheld ultrasound for measuring arm artery size and blood flow
Scientific title
A single-group clinical performance study of inter-system agreement between the VxWave Ultrasound Imaging System and a commercially available ultrasound system (Philips Lumify) for peak systolic velocity and vessel diameter of the upper limb arteries in adults
Additional trial identifiers [1] 318705 0
CIP-2 (Vexev Pty Ltd protocol number)
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Peripheral vascular disease 343925 0
Haemodialysis vascular access planning 343926 0
Condition category
Condition code
Cardiovascular 340067 340067 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Investigational device

The VxWave Ultrasound Imaging System (Vexev Pty Ltd, Australia) is a robotic tomographic duplex ultrasound system. The participant rests the study arm on a scan bed with standard ultrasound gel applied to the arm. A probe beneath the bed moves along the limb under automated motion control to acquire B-mode and spectral Doppler images of the upper limb arteries. A single trained Vexev staff member operates the system.

Study visit

Each participant attends one study visit of approximately 2 hours at Vexev Pty Ltd, Surry Hills, NSW. One arm is scanned first with the VxWave system at three prespecified locations: the proximal brachial artery, distal brachial artery and mid-radial artery. The locations are then marked on the skin. In a separate room, a registered vascular sonographer scans the same arm at the same locations using standard handheld ultrasound, the comparator. Participants complete a four-item comfort questionnaire after the VxWave scan.

Nested repeatability sub-study

The first 20 consecutive participants after Participant ID 030 who complete the comparator scan undergo a third scan, which repeats the handheld ultrasound (comparator) scan on the same arm at the same three locations. After the first comparator scan, the probe is removed, the gel is wiped off and the participant rests for at least 2 minutes before the repeat scan. The third scan is expected to take up to approximately 15 minutes and is performed by the same registered vascular sonographer who performed the first comparator scan. The study visit lasts up to approximately 2 hours 15 minutes for participants having a repeat comparator scan.

Optional second visit

Participants may return for a second visit to have the other arm scanned. At this visit, participants undergo one VxWave scan and one handheld ultrasound (comparator) scan of the other arm at the same three locations, following the same procedures as the first visit. No repeat comparator scan is performed at the second visit. Data from the optional second visit contribute to the primary outcomes and to the secondary outcomes (other than the nested repeatability sub-study outcomes) as additional paired observations, with arm nested within participant in the mixed-effects model.

Image measurement and blinding

A single qualified vascular sonographer who did not acquire the images measures vessel diameter and peak systolic velocity offline after the visit. The sonographer uses VxView, Vexev’s cloud reporting software, for VxWave data and OsiriX MD for comparator data. Randomly generated dataset IDs conceal participant identity and which datasets are paired.

Adherence and fidelity

Scan completion and timing are recorded using the VxWave console log and the electronic case report form. Image acquisition follows prespecified ultrasound imaging standards. No clinical decisions are made from VxWave findings during the study
Intervention code [1] 335594 0
Diagnosis / Prognosis
Description of the comparator or control
Comparator: Philips Lumify portable ultrasound system with L12-4 linear array probe (Philips Medical Systems), operated by a currently registered expert vascular sonographer, scanning the same arm at the same three locations during the same visit. Each participant acts as their own control (within-participant paired comparison). The comparator is used according to its approved labelling and represents standard vascular duplex ultrasound, the comparator will obtain B-mode and spectral data.
Control group
Active

Outcomes
Primary outcome [1] 347211 0
Inter-system agreement in arterial vessel diameter (mm) between the VxWave Ultrasound Imaging System and the comparator (Philips Lumify), at three pre-specified upper limb locations (proximal brachial, distal brachial and mid-radial artery). Reported as mean bias and 95% limits of agreement (VxWave minus comparator); agreement acceptable if the 95% limits of agreement lie within +/-0.5 mm. Arterial vessel diameter between the two systems for all three locations will be assessed together as the primary outcome - with stratified analysis for each region.
Timepoint [1] 347211 0
At the study visit and, where attended, the optional second visit (images acquired at the visit; measured offline after acquisition).
Primary outcome [2] 347212 0
Inter-system agreement in peak systolic velocity (PSV) between the VxWave Ultrasound Imaging System and the comparator (Philips Lumify), at the same three upper limb locations, on the relative percentage scale. Reported descriptively as mean percentage bias and 95% limits of agreement (no acceptance criterion); absolute (cm/s) agreement reported as a sensitivity analysis. Peak systolic velocity between the two systems for all three locations will be assessed together as the primary outcome - with stratified analysis for each region.
Timepoint [2] 347212 0
At the study visit and, where attended, the optional second visit (images acquired at the visit; measured offline after acquisition).
Secondary outcome [1] 469495 0
Scan completion: percentage of participants for whom the VxWave Ultrasound Imaging System completed the peripheral vascular imaging exam with data of diagnostic quality (measurements obtainable at at least two of three locations, B-mode and Doppler, within 50 minutes).
Timepoint [1] 469495 0
At the study visit and, where attended, the optional second visit.
Secondary outcome [2] 469496 0
Time required to complete the ultrasound scan with the VxWave Ultrasound Imaging System (minutes).
Timepoint [2] 469496 0
At the study visit and, where attended, the optional second visit.
Secondary outcome [3] 469497 0
Participant comfort during the VxWave scan.
Timepoint [3] 469497 0
Immediately after the VxWave scan at the study visit.
Secondary outcome [4] 469498 0
Nested repeatability sub-study: repeatability of the reference (comparator, Philips Lumify) measurement of vessel diameter (mm), reported as the mean difference and 95% limits of agreement between first and repeat comparator measurements, with repeatability coefficient. All three locations (proximal brachial, distal brachial and mid-radial artery) will be assessed together as one outcome, with stratified analysis for each location.
Timepoint [4] 469498 0
At the first study visit.
Secondary outcome [5] 469499 0
Device deficiencies: percentage of executed VxWave scans with a reported device deficiency, regardless of whether the scan was completed.
Timepoint [5] 469499 0
From the start of the VxWave scan to the end of the study visit.
Secondary outcome [6] 469500 0
Safety: percentage of executed VxWave scans associated with an adverse event (AE) or adverse device effect (ADE), including serious events.
Timepoint [6] 469500 0
From the start of the study visit until resolution of any adverse event.
Secondary outcome [7] 470689 0
Nested repeatability sub-study: repeatability of the reference (comparator, Philips Lumify) measurement of peak systolic velocity (PSV, relative %), reported as the mean difference and 95% limits of agreement between first and repeat comparator measurements, with repeatability coefficient. All three locations (proximal brachial, distal brachial and mid-radial artery) will be assessed together as one outcome, with stratified analysis for each location.
Timepoint [7] 470689 0
At the first study visit.

Eligibility
Key inclusion criteria
1. Age 21 years or older and able to provide written informed consent.
2. Complete upper limb(s).
Participants may be referred from the Eastern Suburbs Vascular Clinic (Prince of Wales Hospital, Randwick) for specialist vascular consultation, or recruited from the general population.
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Unable to provide informed consent.
2. Unable or unwilling to place the study limb onto the VxWave scanning bed.
3. Poses an infection risk to site staff and/or other participants.
4. Open or healing wound on the study limb.
5. Known abnormal upper limb vascular anatomy that would make scanning at the protocol locations infeasible.
6. Known allergy to parabens (present in standard ultrasound gels).
7. Previous history of upper limb vascular surgery.
8. Any other reason at the discretion of the Principal Investigator.
Eligibility for criteria 5 and 7 is based on participant self-reported history.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable - no randomisation of treatment allocation. All participants are scanned with the VxWave system first, then the comparator. Dataset IDs used for blinding are generated with a documented, cryptographically random procedure; measurement order follows dataset IDs rather than acquisition order. Repeat comparator acquisition is assigned to the first 20 consecutive participants after Participant ID 030 who complete the comparator scan.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Other
Other design features
Within-participant paired method-comparison (agreement) study: each participant has the same arm scanned with the investigational VxWave Ultrasound Imaging System and the comparator (Philips Lumify) at the same visit and the same three pre-specified arterial locations. Measurements are made offline by a single blinded vascular sonographer who did not acquire the images. A nested repeatability sub-study repeats the comparator acquisition after probe lift-off in 20 participants to characterise the reference measurement pathway. Optional second visit for the contralateral arm (one VxWave and one comparator scan; data contribute to the primary and secondary outcome analyses, with arm nested within participant).
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The study is estimation-based (agreement), not hypothesis testing. Sample size is justified by the expected precision of the bias and limits of agreement: 50 participants with successful scans (per-protocol set) x 3 locations = 150 paired observations; enrolment stops at 50 per-protocol or 85 full-analysis-set participants. Illustrative 95% CI half-widths for the limits of agreement at an assumed between-system diameter SD of 0.15 mm are +/-0.042 mm (independence) to +/-0.072 mm (full within-participant clustering), well within the +/-0.5 mm agreement margin.

Primary analysis: multilevel Bland-Altman analysis using a linear mixed-effects model with a random participant intercept, and arm nested within participant where optional second-visit (contralateral arm) data are included (REML); 95% limits of agreement = mean bias +/- 1.96 x sqrt(between- + within-participant variance), with 95% CIs for bias and limits. Diameter agreement is acceptable if the 95% limits of agreement (LOA) lie within +/-0.5 mm (margin based on Zonnebeld et al. 2017 inter-operator LOA and vessel-mapping decision thresholds). PSV agreement analysed on the symmetric relative percentage scale (descriptive), with absolute cm/s as sensitivity analysis. Inter-system reliability by ICC(2,1) absolute agreement from the mixed model.

Secondary: repeatability of the comparator pathway by Bland-Altman (repeat minus first, 20 participants x 3 locations), reported alongside inter-system LOA with the ratio of half-widths and its 95% CI (descriptive, no threshold). Continuous variables as mean, SD and 95% CI; comfort scores as median/IQR or proportions. Full analysis set for safety; per-protocol set for agreement and scan-time outcomes. Analysis after final database lock; no interim analysis.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 30383 0
Prince of Wales Hospital - Randwick
Recruitment postcode(s) [1] 46799 0
2031 - Randwick
Recruitment postcode(s) [2] 46800 0
2010 - Surry Hills

Funding & Sponsors
Funding source category [1] 323270 0
Commercial sector/Industry
Name [1] 323270 0
Vexev Pty Ltd
Country [1] 323270 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Vexev Pty Ltd
Address
Suite 601, 78 Kippax Street, Surry Hills NSW 2010
Country
Australia
Secondary sponsor category [1] 326245 0
None
Name [1] 326245 0
Address [1] 326245 0
Country [1] 326245 0
Other collaborator category [1] 284147 0
Commercial sector/Industry
Name [1] 284147 0
Southern Star Research Pty Ltd (Contract Research Organisation)
Address [1] 284147 0
Level 14, 90 Arthur Street, North Sydney NSW 2060
Country [1] 284147 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321669 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 321669 0
Ethics committee country [1] 321669 0
Australia
Date submitted for ethics approval [1] 321669 0
30/04/2023
Approval date [1] 321669 0
18/01/2024
Ethics approval number [1] 321669 0
2022-08-942

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154462 0
Dr Tam Nguyen
Address 154462 0
Vexev Pty Ltd, Suite 501, 78 Kippax Street, Surry Hills NSW 2010
Country 154462 0
Australia
Phone 154462 0
+61 421 035 102
Fax 154462 0
Email 154462 0
Contact person for public queries
Name 154463 0
Michael Cartmill
Address 154463 0
Vexev Pty Ltd, Suite 601, 78 Kippax Street, Surry Hills NSW 2010
Country 154463 0
Australia
Phone 154463 0
+61 400 223 656
Fax 154463 0
Email 154463 0
Contact person for scientific queries
Name 154464 0
Michael Cartmill
Address 154464 0
Vexev Pty Ltd, Suite 601, 78 Kippax Street, Surry Hills NSW 2010
Country 154464 0
Australia
Phone 154464 0
+61 400 223 656
Fax 154464 0
Email 154464 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data are commercial-in-confidence to the sponsor (medical device performance study) and participants have not consented to sharing of their individual data. Aggregate results will be published.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.